DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS) today reported financial results for the third quarter of 2015.
“Earlier this month, the FDA approved ARISTADA™ as the first long-acting atypical antipsychotic for the treatment of schizophrenia with both once-monthly and six-week dosing. Our nationwide commercial launch is underway and we are delighted to bring this important new treatment option to patients and the treatment community,” said Richard Pops, Chief Executive Officer of Alkermes.
Help employers find you! Check out all the jobs and post your resume.
“Earlier this month, the FDA approved ARISTADA™ as the first long-acting atypical antipsychotic for the treatment of schizophrenia with both once-monthly and six-week dosing. Our nationwide commercial launch is underway and we are delighted to bring this important new treatment option to patients and the treatment community,” said Richard Pops, Chief Executive Officer of Alkermes.
Help employers find you! Check out all the jobs and post your resume.
